메뉴 건너뛰기




Volumn 58, Issue 11, 2014, Pages 6879-6885

Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis

Author keywords

[No Author keywords available]

Indexed keywords

FOSAMPRENAVIR; METOCLOPRAMIDE; PHENYTOIN; POSACONAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RIFAMPICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; CARBAMIC ACID DERIVATIVE; NUCLEIC ACID SYNTHESIS INHIBITOR; ORGANOPHOSPHATE; SULFONAMIDE; TRIAZOLE DERIVATIVE;

EID: 84908299224     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03777-14     Document Type: Article
Times cited : (64)

References (44)
  • 3
    • 13244268757 scopus 로고    scopus 로고
    • Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations
    • Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220. http://dx.doi.org/10.2165/00003088-200544020-00006.
    • (2005) Clin. Pharmacokinet. , vol.44 , pp. 211-220
    • Ezzet, F.1    Wexler, D.2    Courtney, R.3    Krishna, G.4    Lim, J.5    Laughlin, M.6
  • 4
    • 62949244126 scopus 로고    scopus 로고
    • Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers
    • Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
    • (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 958-966
    • Krishna, G.1    Moton, A.2    Ma, L.3    Medlock, M.M.4    McLeod, J.5
  • 5
    • 80053609420 scopus 로고    scopus 로고
    • Effect of pH and comedication on gastrointestinal absorption of posaconazole
    • Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. 2011. Effect of pH and comedication on gastrointestinal absorption of posaconazole. Clin. Pharmacokinet. 50:725-734. http://dx.doi.org/10.2165/11592630-000000000-00000.
    • (2011) Clin. Pharmacokinet. , vol.50 , pp. 725-734
    • Walravens, J.1    Brouwers, J.2    Spriet, I.3    Tack, J.4    Annaert, P.5    Augustijns, P.6
  • 6
    • 84868033749 scopus 로고    scopus 로고
    • Multicenter study of posaconazole therapeutic drug monitoring: Exposure-response relationship and factors affecting concentration
    • Dolton MJ, Ray JE, Chen SCA, Ng K, Pont L, McLachlan AJ. 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56:5503-5510. http://dx.doi.org/10.1128/AAC.00802-12.
    • (2012) Antimicrob. Agents Chemother. , vol.56 , pp. 5503-5510
    • Dolton, M.J.1    Ray, J.E.2    Chen, S.C.A.3    Ng, K.4    Pont, L.5    McLachlan, A.J.6
  • 7
    • 80051792869 scopus 로고    scopus 로고
    • Posaconazole plasma concentrations in critically ill patients
    • Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. 2011. Posaconazole plasma concentrations in critically ill patients. Ther. Drug Monit. 33:387-392. http://dx.doi.org/10.1097/FTD.0b013e31821fb197.
    • (2011) Ther. Drug Monit. , vol.33 , pp. 387-392
    • Ray, J.1    Campbell, L.2    Rudham, S.3    Nguyen, Q.4    Marriott, D.5
  • 9
    • 84861116449 scopus 로고    scopus 로고
    • Posaconazole exposure-response relationship: Evaluating the utility of therapeutic drug monitoring
    • Dolton MJ, Ray JE, Marriott D, Mclachlan AJ. 2012. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:2806-2813. http://dx.doi.org/10.1128/AAC.05900-11.
    • (2012) Antimicrob. Agents Chemother. , vol.56 , pp. 2806-2813
    • Dolton, M.J.1    Ray, J.E.2    Marriott, D.3    Mclachlan, A.J.4
  • 11
    • 77953809369 scopus 로고    scopus 로고
    • Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma
    • Jang SH, Colangelo PM, Gobburu JVS. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119. http://dx.doi.org/10.1038/clpt.2010.64.
    • (2010) Clin. Pharmacol. Ther. , vol.88 , pp. 115-119
    • Jang, S.H.1    Colangelo, P.M.2    Gobburu, J.V.S.3
  • 12
    • 79951811382 scopus 로고    scopus 로고
    • Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections
    • Cornely OA, Ullmann AJ. 2011. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89:351-352. http://dx.doi.org/10.1038/clpt.2010.261.
    • (2011) Clin. Pharmacol. Ther. , vol.89 , pp. 351-352
    • Cornely, O.A.1    Ullmann, A.J.2
  • 13
    • 84892534686 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis
    • Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ. 2013. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev. Anti Infect. Ther. 11:931-941. http://dx.doi.org/10.1586/14787210.2013.826989.
    • (2013) Expert Rev. Anti Infect. Ther. , vol.11 , pp. 931-941
    • Seyedmousavi, S.1    Mouton, J.W.2    Verweij, P.E.3    Brüggemann, R.J.4
  • 14
    • 84861229084 scopus 로고    scopus 로고
    • Posaconazole treatment in hematology patients: A pilot study of therapeutic drug monitoring
    • Crombag M-RBS, Huisman C, Kemper EM, Brüggemann RJM, Bijleveld YA. 2012. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring. Ther. Drug Monit. 34:320-325. http://dx.doi.org/10.1097/FTD.0b013e31824d135c.
    • (2012) Ther. Drug Monit. , vol.34 , pp. 320-325
    • M-Rbs, C.1    Huisman, C.2    Kemper, E.M.3    Brüggemann, R.J.M.4    Bijleveld, Y.A.5
  • 15
    • 75749102569 scopus 로고    scopus 로고
    • Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene
    • Mavridou E, Bruggemann RJM, Melchers WJG, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865. http://dx.doi.org/10.1128/AAC.00931-09.
    • (2010) Antimicrob. Agents Chemother. , vol.54 , pp. 860-865
    • Mavridou, E.1    Bruggemann, R.J.M.2    Melchers, W.J.G.3    Mouton, J.W.4    Verweij, P.E.5
  • 19
    • 79951949693 scopus 로고    scopus 로고
    • A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis
    • Bryant AM, Slain D, Cumpston A, Craig M. 2011. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int. J. Antimicrob. Agents 37:266-269. http://dx.doi.org/10.1016/j.ijantimicag.2010.11.021.
    • (2011) Int. J. Antimicrob. Agents , vol.37 , pp. 266-269
    • Bryant, A.M.1    Slain, D.2    Cumpston, A.3    Craig, M.4
  • 20
    • 84908304514 scopus 로고    scopus 로고
    • revised 11/2013 fda-docs/label/2013/205053s000lbl.pdf Accessed 3 March 2014
    • Merck Inc. 2014. Noxafil prescribing information, revised 11/2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/205053s000lbl.pdf. Accessed 3 March 2014.
    • (2014) Noxafil Prescribing Information
  • 22
    • 84865470874 scopus 로고    scopus 로고
    • Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model)
    • Shen J, Boeckmann A, Vick A. 2012. Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J. Pharmacokinet. Pharmacodyn. 39:251-262. http://dx.doi.org/10.1007/s10928-012-9247-3.
    • (2012) J. Pharmacokinet. Pharmacodyn. , vol.39 , pp. 251-262
    • Shen, J.1    Boeckmann, A.2    Vick, A.3
  • 23
    • 79957451960 scopus 로고    scopus 로고
    • Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models
    • Bergstrand M, Hooker A, Wallin J, Karlsson M. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.AAPS J. 13:143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
    • (2011) AAPS J. , vol.13 , pp. 143-151
    • Bergstrand, M.1    Hooker, A.2    Wallin, J.3    Karlsson, M.4
  • 24
    • 74549125472 scopus 로고    scopus 로고
    • Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
    • AbuTarif MA, Krishna G, Statkevich P. 2010. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr. Med. Res. Opin. 26:397-405. http://dx.doi.org/10.1185/03007990903485056.
    • (2010) Curr. Med. Res. Opin. , vol.26 , pp. 397-405
    • AbuTarif, M.A.1    Krishna, G.2    Statkevich, P.3
  • 26
    • 84864286296 scopus 로고    scopus 로고
    • Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
    • Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, Kreuzer KA, Hallek M, Kohl V. 2012. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur. J. Clin. Pharmacol. 68:987-995. http://dx.doi.org/10.1007/s00228-012-1212-y.
    • (2012) Eur. J. Clin. Pharmacol. , vol.68 , pp. 987-995
    • Vehreschild, J.J.1    Müller, C.2    Farowski, F.3    Vehreschild, M.J.4    Cornely, O.A.5    Fuhr, U.6    Kreuzer, K.A.7    Hallek, M.8    Kohl, V.9
  • 27
    • 85010936123 scopus 로고    scopus 로고
    • London, United Kingdom Accessed 1 November 2013
    • European Medicines Agency. 2005. Noxafil: EPAR - scientific discussion. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific-Discussion/human/000610/WC500037781.pdf. Accessed 1 November 2013.
    • (2005) Noxafil: EPAR - Scientific Discussion
  • 28
    • 70350326279 scopus 로고    scopus 로고
    • Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers
    • Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, Beresford E, Komjathy S. 2009. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 53:4749-4752. http://dx.doi.org/10.1128/AAC.00889-09.
    • (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 4749-4752
    • Krishna, G.1    Ma, L.2    Vickery, D.3    Yu, X.4    Wu, I.5    Power, E.6    Beresford, E.7    Komjathy, S.8
  • 29
    • 54749151049 scopus 로고    scopus 로고
    • Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
    • Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232. http://dx.doi.org/10.1592/phco.28.10.1223.
    • (2008) Pharmacotherapy , vol.28 , pp. 1223-1232
    • Krishna, G.1    AbuTarif, M.2    Xuan, F.3    Martinho, M.4    Angulo, D.5    Cornely, O.A.6
  • 30
    • 36849064207 scopus 로고    scopus 로고
    • Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease
    • Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. http://dx.doi.org/10.1592/phco.27.12.1627.
    • (2007) Pharmacotherapy , vol.27 , pp. 1627-1636
    • Krishna, G.1    Martinho, M.2    Chandrasekar, P.3    Ullmann, A.J.4    Patino, H.5
  • 31
    • 84860117262 scopus 로고    scopus 로고
    • Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection
    • Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJGT, Krishna G, Ma L, Huyck S, McCarthy MC. 2012. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob. Agents Chemother. 56:2652-2658. http://dx.doi.org/10.1128/AAC.05937-11.
    • (2012) Antimicrob. Agents Chemother. , vol.56 , pp. 2652-2658
    • Cornely, O.A.1    Helfgott, D.2    Langston, A.3    Heinz, W.4    Vehreschild, J.J.5    Vehreschild, M.J.G.T.6    Krishna, G.7    Ma, L.8    Huyck, S.9    McCarthy, M.C.10
  • 33
    • 34347211017 scopus 로고    scopus 로고
    • Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men
    • Krishna G, Sansone-Parsons A, Kantesaria B. 2007. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr. Med. Res. Opin. 23:1415-1422. http://dx.doi.org/10.1185/030079907X187937.
    • (2007) Curr. Med. Res. Opin. , vol.23 , pp. 1415-1422
    • Krishna, G.1    Sansone-Parsons, A.2    Kantesaria, B.3
  • 34
    • 33947354866 scopus 로고    scopus 로고
    • Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men
    • Krishna G, Parsons A, Kantesaria B, Mant T. 2007. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr. Med. Res. Opin. 23:545-552. http://dx.doi.org/10.1185/030079906X167507.
    • (2007) Curr. Med. Res. Opin. , vol.23 , pp. 545-552
    • Krishna, G.1    Parsons, A.2    Kantesaria, B.3    Mant, T.4
  • 35
    • 77749277056 scopus 로고    scopus 로고
    • Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations
    • Hohmann C, Kang EM, Jancel T. 2010. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin. Infect. Dis. 50:939-940. http://dx.doi.org/10.1086/650740.
    • (2010) Clin. Infect. Dis. , vol.50 , pp. 939-940
    • Hohmann, C.1    Kang, E.M.2    Jancel, T.3
  • 36
    • 77956593204 scopus 로고    scopus 로고
    • Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: An overview
    • Lipp H-P. 2010. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br. J. Clin. Pharmacol. 70:471-480. http://dx.doi.org/10.1111/j.1365-2125.2010.03680.x.
    • (2010) Br. J. Clin. Pharmacol. , vol.70 , pp. 471-480
    • Lipp, H.-P.1
  • 38
    • 8844262477 scopus 로고    scopus 로고
    • Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs
    • Anderson GD. 2004. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 63(10 Suppl 4):S3-S8. http://dx.doi.org/10.1212/WNL.63.10-suppl-4.S3.
    • (2004) Neurology , vol.63 , Issue.10 , pp. S3-S8
    • Anderson, G.D.1
  • 39
    • 0029758162 scopus 로고    scopus 로고
    • Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver
    • Oesch F, Arand M, Benedetti MS, Castelli MG, Dostert P. 1996. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J. Antimicrob. Chemother. 37:1111-1119. http://dx.doi.org/10.1093/jac/37.6.1111.
    • (1996) J. Antimicrob. Chemother. , vol.37 , pp. 1111-1119
    • Oesch, F.1    Arand, M.2    Benedetti, M.S.3    Castelli, M.G.4    Dostert, P.5
  • 42
    • 84898452706 scopus 로고    scopus 로고
    • Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology
    • Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 69:1162-1176. http://dx.doi.org/10.1093/jac/dkt508.
    • (2014) J. Antimicrob. Chemother. , vol.69 , pp. 1162-1176
    • Ashbee, H.R.1    Barnes, R.A.2    Johnson, E.M.3    Richardson, M.D.4    Gorton, R.5    Hope, W.W.6
  • 43
    • 84903899191 scopus 로고    scopus 로고
    • Understanding variability with voriconazole using a population pharmacokinetic approach: Implications for optimal dosing
    • Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. 2014. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J. Antimicrob. Chemother. 69:1633-1641. http://dx.doi.org/10.1093/jac/dku031.
    • (2014) J. Antimicrob. Chemother. , vol.69 , pp. 1633-1641
    • Dolton, M.J.1    Mikus, G.2    Weiss, J.3    Ray, J.E.4    McLachlan, A.J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.